Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07103148RecruitingPhase 3
Study of a Yellow Fever Vaccine in Young Children
This trial tests a new yellow fever vaccine in young children. It will see if the vaccine is safe and produces a good immune response, including when given with the MMR vaccine.
San Pedro SulaAges 9 months–5 years - NCT06843317RecruitingPhase 1
RSV vaccine booster for older adults
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Phoenix, ArizonaAges 60–85 - NCT06885853Recruiting
Long-term immune response to mpox booster in men on PrEP
This study tests how well a booster dose of the MVA-BN mpox vaccine keeps working over time in men who are on or starting PrEP for HIV prevention.
Paris, ParisAges 18 years+ - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07094711RecruitingPhase 2
BCG vaccine boost for MAC lung disease
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
Charlottesville, VirginiaAges 18 years+ - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07085702RecruitingPhase 1
Testing a new Strep A vaccine in healthy young adults
This study tests a new vaccine designed to protect against Group A Strep bacteria. It will check how safe the vaccine is and how well it boosts your immune system. Healthy young adults between 18 and 25 years old may be eligible.
Botany, New South WalesAges 18–25 - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07054099RecruitingPhase 3
Testing a chickenpox vaccine for children ages 1 to 12
This study tests a new chickenpox vaccine (MG1111, also called BARYCELA Inj.) in healthy children aged 1 to 12 years. It checks how well the vaccine works and if it is safe, with two doses given over time.
Khon Kaen, Changwat Khon KaenAges 1–12 - NCT07050732RecruitingPhase 2
Testing RSV vaccine in people with weakened immune systems
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Baltimore, MarylandAges 18 years+ - NCT07036159RecruitingPhase 2
Malaria vaccine safety study for children ages 5 months to 5 years
This trial tests a new malaria vaccine in healthy children. It aims to see if the vaccine is safe and how well it works in children who have had their regular childhood shots.
KigaliAges 5 months–5 years - NCT07025681RecruitingPhase 3
Comparing a new erythropoietin to Eprex for healthy volunteers
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
Dhaka, Dhaka DivisionAges 18 years+ - NCT07016152RecruitingPhase 1
A study of a Klebsiella vaccine for healthy adults
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
TaipeiAges 18–50 - NCT07013747RecruitingPhase 1/Phase 2
Acne mRNA vaccine for mild acne
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
Encino, CaliforniaAges 18–45 - NCT06997627RecruitingPhase 1/Phase 2
Safety and immune response study of GC3111B vaccine in healthy adults
This trial tests a new vaccine called GC3111B to see if it is safe and helps the body build protection against diphtheria, tetanus, and pertussis (whooping cough). It is for healthy adults who have not had a similar vaccine in the last 2 years.
SeoulAges 19–64 - NCT06960382RecruitingPhase 1/Phase 2
Cat allergy immunotherapy with lymph node injections
This trial tests a new way to treat cat allergies by giving tiny injections directly into a lymph node (a part of your immune system), instead of under the skin. It aims to see if this method is safe and can reduce cat allergy symptoms, even in people with asthma.
ZurichAges 18–65 - NCT06928753RecruitingPhase 4
Chikungunya vaccine study in Reunion and French Guiana
This study looks at how well the chikungunya vaccine works in real life, how safe it is, and how the body's immune system responds. It is for adults who are eligible for the vaccine according to French health guidelines.
CayenneAges 18 years+ - NCT06863142RecruitingPhase 1
Testing a new flu vaccine with or without adjuvant
This study tests a new investigational flu vaccine (FluMos-v2) with or without an adjuvant (ALFQ) to see how safe, tolerable, and effective it is. It may help protect against multiple flu strains.
Bethesda, MarylandAges 18–50 - NCT06842173RecruitingPhase 1/Phase 2
Safety testing of new bird flu vaccine (H5N8) in adults
This trial tests a new bird flu (H5N8) vaccine for adults aged 18 and older. It looks at how safe the vaccine is and how well it triggers an immune response. The vaccine is given as a shot and includes an adjuvant to boost protection.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT06834100RecruitingPhase 3
Comparing a new meningitis vaccine to an approved one
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
KirovAges 3–55 - NCT06821126RecruitingPhase 1/Phase 2
Nasal spray COVID-19 vaccine booster study for healthy adults
This study tests a new nasal spray COVID-19 vaccine to see how it compares to an mRNA booster shot. It is for healthy adults who have already had at least 3 doses of an mRNA COVID-19 vaccine (or 2 doses plus a confirmed COVID infection) and are looking for a needle-free booster option.
DijonAges 18–60 - NCT06822907RecruitingPhase 4
Testing pneumococcal vaccine during a fever in adults
This trial tests if a pneumococcal vaccine (PCV-20) is safe and works well when given to adults during a fever. It may help protect people with certain health conditions from serious pneumococcal infections.
Saint-Etienne, FranceAges 18–85 - NCT06796686RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
San Francisco, CaliforniaAges 18–55
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.